Karyopharm - oncology

Quote
  • Our boss’ distinguish recorded at helm:
  • Stock price down from $9.55 to $0.97. ~90%
  • Never bought a share on open market, sold hundreds of thousands of shares.
  • Multiple Debt deals.
  • May not reach data readouts despite overwhelmingly early positive data signals.
  • Trials cancelled, multiple phase 3 trials delayed.
  • Stock currently under NASDAQ requirements
  • Multiple unforced errors, like European Assay delay
  • Despite all this getting 95% bonus from board, tons of equity (422,000 shares this year alone!), and not fired for cause with clawback.
  • Given an agent that works in multiple indications, still has not added a single indication from when he took over in 05/2021.
 




anonymous said:
  • Our boss’ distinguish recorded at helm:
  • Stock price down from $9.55 to $0.97. ~90%
  • Never bought a share on open market, sold hundreds of thousands of shares.
  • Multiple Debt deals.
  • May not reach data readouts despite overwhelmingly early positive data signals.
  • Trials cancelled, multiple phase 3 trials delayed.
  • Stock currently under NASDAQ requirements
  • Multiple unforced errors, like European Assay delay
  • Despite all this getting 95% bonus from board, tons of equity (422,000 shares this year alone!), and not fired for cause with clawback.
  • Given an agent that works in multiple indications, still has not added a single indication from when he took over in 05/2021.
Click to expand...
He’s completely incompetent. I don’t know of a better example of the Peter principle.
 












anonymous said:
This company is close to failing. Must find new investors quick!
Click to expand...

News



karyopharm-ceo-richard-paulson-took-over-a-company-worth-v0-13ebijek9z5d1.jpeg
r/KPTI - Karyopharm CEO Richard Paulson took over a company worth ~$1BN. It is now about to be removed from Russell 3000 under his leadership


Upvote2Downvote1comments0 awardsShare

THANK YOU VERY MUCH RICHARD
 




NCCN Cervical and Uterine Panel meeting next week to consider Selinexor incorporation into the NCCN guidelines for Advanced Recurrent Endometrial Cancer. Dates of the panel meeting are June 20-21. The filing for consideration occurred on November 17th requesting Category 1 designation for use in the p53wt patient group
 
































anonymous said:
Short Interest in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Rises By 14.7% - Defense World

Short Interest in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Rises By 14.7%
Click to expand...


This is how confident our leaders are in the BS data they are generating while the pillage the cash....it is so valuable that they had not purchased one dollar worth of stock in open market, a stock that sits under a buck. They see absolutely zero value in a stock that sits under a buck but the clown at the top says that the trials can yield billion run rate a year......lmfao.....does he really think we are fools????? Never trust a canuck.


NASDAQ Sourced
 
















anonymous said:
Wonder how they can maintain the executive salary and compensation burn rate with no cash coming in.....hmmmmm

DermTech 0.1
Click to expand...
Thanks really their talent….dangle shiny object which is just an illusion while they jammed their pockets with the remaining cash. Then blame external factors to veil their incompetence and lay groundwork to ward off law action lawsuits which will ramp
 












Top Bottom
Back
Quote